+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts



Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts



Leukemia and Lymphoma 26(3-4): 299-306



The prognostic significance of CD34 antigen expression in acute myelogenous leukemia (AML) is controversial. Most studies to date have reported on CD34 positivity and not the level of antigen present. In this study of 62 patients with de novo AML, 48 (77%) patients were CD34+ in varying levels (0-85 mean channels of fluorescence (MCF)). Forty seven of 62 were treated with combination chemotherapy and 39 (83%) of them achieved complete remission (CR). Patients with CD34- blasts were more likely to achieve CR; however, this trend was not statistically significant (p = .11). On the other hand, patients with higher levels of CD34 antigen on the blasts were less likely to attain CR (p < 0.001, multivariate analysis). The patients who achieved CR expressed lower levels of CD34 (0-57; median 9 MCF) as compared to those who did not achieve CR (15-85; median 30 MCF). Of the other antigens tested, partial or complete absence of CD33 (CD33 absent in > or =25% blasts) correlated with failure to achieve CR (p = 0.0029). These results are in keeping with the hypothesis that more primitive AML blasts with high levels of CD34 are chemoresistant.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046385784

Download citation: RISBibTeXText

PMID: 9322892

DOI: 10.3109/10428199709051779


Related references

Prognostic Significance of Fas Antigen Expression by Leukemic Blasts in Patients with Acute Myelogenous Leukemia. Blood 100(11): Abstract No 4446, 2002

CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. Part B Clinical Cytometry 64(1): 18-27, 2005

AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 94(2): 832-833, 1999

Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leukemia and Lymphoma 19(3-4): 235-241, 1995

Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. Blood 92(11): 4485-4487, 1998

Leptin in human acute myelogenous leukemia: Studies of in vivo levels and in vitro effects on native functional leukemic blasts. Haematologica 87(6): 584-595, 2002

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. Leukemia Research 65: 34-41, 2018

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. Leukemia Research 65: 34-41, 2018

Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective. Blood Research 49(4): 241-245, 2014

Differential responses of CD34-positive acute myelogenous leukemic blasts to the costimulating effects of stem cell factor with GM-CSF and/or IL-3. Yonsei Medical Journal 36(1): 26-36, 1995

Expression of an acute myelogenous leukemia associated antigen nhl 30.5 on immature leukemic cells. Reinherz, E L Et Al (Ed ) Leukocyte Typing Ii, Vol 3 Human Myeloid And Hematopoietic Cells; Second International Workshop on Human Leukocyte Differentiation Antigens, Boston, Mass , Usa, Sept 17-20, 1984 Xvi+366p Springer-Verlag New York, Inc : Secaucus, N J , Usa; Berlin, West Germany Illus 315-326, 1986

Multidrug resistance gene transcript or CD34 antigen expression levels do not predict for complete remissions in de novo adult acute myeloid leukemia An Eastern Cooperative Oncology Group study. Blood 84(10 Suppl. 1): 377A, 1994

High levels of p52/p46 Shc tyrosine-phosphorylation in CD34+ acute myelogenous leukemia. Blood 94(10 Suppl. 1 Part 2): 217b, 1999

Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34- blasts from acute myelogenous leukemia. Blood 78(1): 197-204, 1991

CD66c (KOR-SA3544) antigen expression of leukemic blasts in pediatric acute myeloid leukemia with TLS/FUS-ERG fusion transcript. International Journal of Laboratory Hematology 39(6): E147-E150, 2017